

Pepe Alcami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7192471/publications.pdf>

Version: 2024-02-01

209
papers

8,178
citations

36303

51
h-index

66911

78
g-index

230
all docs

230
docs citations

230
times ranked

11498
citing authors

#	ARTICLE	IF	CITATIONS
1	Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. <i>EMBO Reports</i> , 2000, 1, 190-196.	4.5	335
2	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet</i> , The, 2021, 398, 121-130.	13.7	316
3	Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. <i>Nature Reviews Microbiology</i> , 2009, 7, 798-812.	28.6	235
4	HIV enhancer activity perpetuated by NF- κ B induction on infection of monocytes. <i>Nature</i> , 1991, 350, 709-712.	27.8	209
5	Hydrogen peroxide increases extracellular matrix mRNA through TGF- β 2 in human mesangial cells. <i>Kidney International</i> , 2001, 59, 87-95.	5.2	196
6	TRAF Family Proteins Link PKR with NF- κ B Activation. <i>Molecular and Cellular Biology</i> , 2004, 24, 4502-4512.	2.3	147
7	Therapeutic Immunization with Dendritic Cells Loaded with Heat-Inactivated Autologous HIV-1 in Patients with Chronic HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2005, 191, 1680-1685.	4.0	147
8	Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. <i>Journal of Virology</i> , 1994, 68, 5730-5737.	3.4	146
9	Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2718-2721.	2.2	135
10	Overview of SARS-CoV-2 infection in adults living with HIV. <i>Lancet HIV</i> , the, 2021, 8, e294-e305.	4.7	129
11	Activation of NF- κ B by the dsRNA-dependent protein kinase, PKR involves the κ B kinase complex. <i>Oncogene</i> , 2000, 19, 1369-1378.	5.9	125
12	Multivalent Manno-Glyconanoparticles Inhibit DC-SIGN-Mediated HIV-1 Trans-Infection of Human T Cells. <i>ChemBioChem</i> , 2009, 10, 1806-1809.	2.6	117
13	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. <i>Nature Communications</i> , 2019, 10, 2355.	12.8	116
14	Imperatorin Inhibits HIV-1 Replication through an Sp1-dependent Pathway. <i>Journal of Biological Chemistry</i> , 2004, 279, 37349-37359.	3.4	115
15	Plasma Stromal Cell-Derived Factor (SDF)-1 Levels, SDF1- β 2A Genotype, and Expression of CXCR4 on T Lymphocytes: Their Impact on Resistance to Human Immunodeficiency Virus Type 1 Infection and Its Progression. <i>Journal of Infectious Diseases</i> , 2002, 186, 922-931.	4.0	110
16	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report. <i>PLoS ONE</i> , 2009, 4, e4505.	2.5	109
17	Stimulation of a human T-cell clone with anti-CD3 or tumor necrosis factor induces NF-kappa B translocation but not human immunodeficiency virus 1 enhancer-dependent transcription.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 7861-7865.	7.1	108
18	Genomic organization and promoter characterization of human CXCR4 gene1. <i>FEBS Letters</i> , 1998, 426, 271-278.	2.8	107

#	ARTICLE	IF	CITATIONS
19	Beyond plasticity: the dynamic impact of electrical synapses on neural circuits. <i>Nature Reviews Neuroscience</i> , 2019, 20, 253-271.	10.2	107
20	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 473-478.	4.0	105
21	Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5). <i>Journal of Biological Chemistry</i> , 2011, 286, 33409-33421.	3.4	101
22	The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection.. <i>Journal of Clinical Investigation</i> , 1997, 100, 497-502.	8.2	101
23	A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	100
24	Chemokine expression by systemic sclerosis fibroblasts: Abnormal regulation of monocyte chemoattractant protein 1 expression. <i>Arthritis and Rheumatism</i> , 2001, 44, 1382-1386.	6.7	97
25	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. <i>Nature Medicine</i> , 2020, 26, 1339-1350.	30.7	96
26	The Hepatitis B Virus X Protein Induces HIV-1 Replication and Transcription in Synergy with T-cell Activation Signals. <i>Journal of Biological Chemistry</i> , 2001, 276, 35435-35443.	3.4	95
27	Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. <i>Clinical and Experimental Immunology</i> , 2001, 123, 36-41.	2.6	78
28	NF-kappa B-dependent induction of the NF-kappa B p50 subunit gene promoter underlies self-perpetuation of human immunodeficiency virus transcription in monocytic cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 7826-7830.	7.1	74
29	New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection. <i>Journal of Biological Chemistry</i> , 2011, 286, 4978-4990.	3.4	73
30	Somatostatin-positive interneurons in the dentate gyrus of mice provide local- and long-range septal synaptic inhibition. <i>ELife</i> , 2017, 6, .	6.0	73
31	Functional Characterization of SDF-1 Proximal Promoter. <i>Journal of Molecular Biology</i> , 2005, 348, 43-62.	4.2	72
32	Activation of blood T lymphocytes down-regulates CXCR4 expression and interferes with propagation of X4 HIV strains. <i>European Journal of Immunology</i> , 1998, 28, 3192-3204.	2.9	71
33	Effect of Mycophenolate Mofetil on Immune Response and Plasma and Lymphatic Tissue Viral Load During and After Interruption of Highly Active Antiretroviral Therapy for Patients With Chronic HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 823-830.	2.1	71
34	A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. <i>Journal of Medical Virology</i> , 2007, 79, 127-137.	5.0	70
35	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). <i>Vaccine</i> , 2011, 29, 8309-8316.	3.8	70
36	Anti-HIV activity of medicinal plant extracts. <i>Journal of Ethnopharmacology</i> , 2001, 77, 113-116.	4.1	69

#	ARTICLE	IF	CITATIONS
37	4-Phenylcoumarins as HIV transcription inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4447-4450.	2.2	69
38	Rate and predictors of progression in elite and viremic HIV-1 controllers. <i>Aids</i> , 2016, 30, 1209-1220.	2.2	69
39	3-Phenylcoumarins as Inhibitors of HIV-1 Replication. <i>Molecules</i> , 2012, 17, 9245-9257.	3.8	67
40	Modifications in the human T cell proteome induced by intracellular HIV-1 Tat protein expression. <i>Proteomics</i> , 2006, 6, S63-S73.	2.2	66
41	Constitutive expression of human immunodeficiency virus (HIV) nef protein in human astrocytes does not influence basal or induced HIV long terminal repeat activity. <i>Journal of Virology</i> , 1990, 64, 3059-3062.	3.4	66
42	The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF- κ B activation. <i>Oncogene</i> , 2001, 20, 385-394.	5.9	64
43	IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle. <i>Cell Reports</i> , 2016, 14, 2100-2107.	6.4	64
44	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II. <i>PLoS ONE</i> , 2012, 7, e36438.	2.5	63
45	G Protein-Dependent CCR5 Signaling Is Not Required for Efficient Infection of Primary T Lymphocytes and Macrophages by R5 Human Immunodeficiency Virus Type 1 Isolates. <i>Journal of Virology</i> , 2003, 77, 2550-2558.	3.4	61
46	HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9475-9480.	7.1	61
47	Quinoline-based compounds as modulators of HIV transcription through NF- κ B and Sp1 inhibition. <i>Antiviral Research</i> , 2010, 87, 338-344.	4.1	59
48	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. <i>Journal of Virology</i> , 2018, 92, .	3.4	58
49	Mesulol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF- κ B pathway. <i>Antiviral Research</i> , 2005, 66, 137-145.	4.1	57
50	Measuring the Firing Rate of High-Resistance Neurons with Cell-Attached Recording. <i>Journal of Neuroscience</i> , 2012, 32, 3118-3130.	3.6	57
51	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1833-1842.	3.0	56
52	Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon. <i>Nucleic Acids Research</i> , 2010, 38, 3287-3307.	14.5	55
53	A Founder Effect Led Early SARS-CoV-2 Transmission in Spain. <i>Journal of Virology</i> , 2021, 95, .	3.4	55
54	SJ23B, a jatrophone diterpene activates classical PKCs and displays strong activity against HIV in vitro. <i>Biochemical Pharmacology</i> , 2009, 77, 965-978.	4.4	54

#	ARTICLE	IF	CITATIONS
55	Environmentally Friendly Procedure Based on Supercritical Fluid Chromatography and Tandem Mass Spectrometry Molecular Networking for the Discovery of Potent Antiviral Compounds from <i>Euphorbia semiperfoliata</i> . <i>Journal of Natural Products</i> , 2017, 80, 2620-2629.	3.0	51
56	Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. <i>Biochemical Pharmacology</i> , 2016, 106, 30-45.	4.4	50
57	Induction of an endothelial cell growth factor by human cytomegalovirus infection of fibroblasts. <i>Journal of General Virology</i> , 1991, 72, 2765-2770.	2.9	50
58	Anti-HIV activity of stilbene-related heterocyclic compounds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4075-4079.	2.2	47
59	The Presence of HIV-1 Tat Protein Second Exon Delays Fas Protein-mediated Apoptosis in CD4+ T Lymphocytes. <i>Journal of Biological Chemistry</i> , 2013, 288, 7626-7644.	3.4	47
60	Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from <i>Cassine xylocarpa</i> and <i>Maytenus cuzcoina</i> . <i>Journal of Natural Products</i> , 2015, 78, 1045-1055.	3.0	47
61	CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts. <i>Cytokine</i> , 2011, 53, 184-190.	3.2	44
62	Estimating functional connectivity in an electrically coupled interneuron network. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4798-E4807.	7.1	44
63	The Carboxyl-terminal Domain of Connexin43 Is a Negative Modulator of Neuronal Differentiation. <i>Journal of Biological Chemistry</i> , 2010, 285, 11836-11845.	3.4	43
64	MC159L protein from the poxvirus molluscum contagiosum virus inhibits NF- κ B activation and apoptosis induced by PKR. <i>Journal of General Virology</i> , 2001, 82, 3027-3034.	2.9	43
65	Prostratin Induces HIV Activation and Downregulates HIV Receptors in Peripheral Blood Lymphocytes. <i>Antiviral Therapy</i> , 2004, 9, 545-554.	1.0	43
66	Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. <i>AIDS Reviews</i> , 2010, 12, 135-48.	1.0	42
67	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. <i>Vaccine</i> , 2011, 29, 5250-5259.	3.8	38
68	The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatins-1. <i>Scientific Reports</i> , 2017, 7, 2385.	3.3	38
69	Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia. <i>Journal of Virology</i> , 2011, 85, 5804-5813.	3.4	37
70	A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2493-2501.	3.0	35
71	Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. <i>Cell Reports</i> , 2022, 38, 110235.	6.4	35
72	Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. <i>AIDS Reviews</i> , 2012, 14, 208-17.	1.0	35

#	ARTICLE	IF	CITATIONS
73	Screening of selected plant extracts for in vitro inhibitory activity on Human Immunodeficiency Virus. <i>Phytotherapy Research</i> , 2002, 16, 550-554.	5.8	34
74	Basal shuttle of NF- κ B/I κ B β in resting T lymphocytes regulates HIV-1 LTR dependent expression. <i>Retrovirology</i> , 2007, 4, 56.	2.0	34
75	Involvement of the Rac1-IRSp53-Wave2-Arp2/3 Signaling Pathway in HIV-1 Gag Particle Release in CD4 T Cells. <i>Journal of Virology</i> , 2015, 89, 8162-8181.	3.4	34
76	Analysis of Non-AIDS-Defining Events in HIV Controllers. <i>Clinical Infectious Diseases</i> , 2016, 62, 1304-1309.	5.8	34
77	Optimal use of maraviroc in clinical practice. <i>Aids</i> , 2008, 22, 2231-2240.	2.2	33
78	Olean-18-ene triterpenoids from Celastraceae species inhibit HIV replication targeting NF- κ B and Sp1 dependent transcription. <i>European Journal of Medicinal Chemistry</i> , 2012, 52, 295-303.	5.5	33
79	Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents. <i>Proteomics</i> , 2008, 8, 852-873.	2.2	31
80	Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. <i>Journal of Virology</i> , 2016, 90, 5231-5245.	3.4	31
81	Negatively Charged Glyconanoparticles Modulate and Stabilize the Secondary Structures of a gp120 V3 Loop Peptide: Toward Fully Synthetic HIV Vaccine Candidates. <i>Bioconjugate Chemistry</i> , 2015, 26, 755-765.	3.6	30
82	Protein Kinase C δ Is a Specific Target for Inhibition of the HIV Type 1 Replication in CD4+ T Lymphocytes*. <i>Journal of Biological Chemistry</i> , 2011, 286, 27363-27377.	3.4	29
83	Transcriptome Sequencing of Peripheral Blood Mononuclear Cells from Elite Controller-Long Term Non Progressors. <i>Scientific Reports</i> , 2019, 9, 14265.	3.3	29
84	Evaluation of the Abbott LCx Quantitative Assay for Measurement of Human Immunodeficiency Virus RNA in Plasma. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1518-1521.	3.9	28
85	Structure-Based Design of an RNA-Binding α -Terphenylene Scaffold that Inhibits HIV-1 Rev Protein Function. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 13405-13409.	13.8	28
86	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw833.	5.8	28
87	LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. <i>Virus Research</i> , 1998, 57, 11-20.	2.2	27
88	Intracellular expression of Tat alters mitochondrial functions in T cells: a potential mechanism to understand mitochondrial damage during HIV-1 replication. <i>Retrovirology</i> , 2015, 12, 78.	2.0	27
89	A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. <i>Retrovirology</i> , 2015, 12, 50.	2.0	27
90	CCR5 structural plasticity shapes HIV-1 phenotypic properties. <i>PLoS Pathogens</i> , 2018, 14, e1007432.	4.7	27

#	ARTICLE	IF	CITATIONS
91	Association between stromal cell-derived factor 1 chemokine gene variant and radiographic progression of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 354-356.	6.7	26
92	Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers. <i>Journal of Virology</i> , 2019, 93, .	3.4	26
93	Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity. <i>Frontiers in Immunology</i> , 2021, 12, 665329.	4.8	26
94	Screening of South American Plants against Human Immunodeficiency Virus: Preliminary Fractionation of Aqueous Extract from <i>Baccharis trinervis</i> .. <i>Biological and Pharmaceutical Bulletin</i> , 2002, 25, 1147-1150.	1.4	25
95	Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. <i>Arthritis and Rheumatism</i> , 2006, 54, 1473-1481.	6.7	25
96	Caspase-3-mediated cleavage of p65/RelA results in a carboxy-terminal fragment that inhibits $\text{I}\kappa\text{B}\alpha$ and enhances HIV-1 replication in human T lymphocytes. <i>Retrovirology</i> , 2008, 5, 109.	2.0	25
97	SDF-1/CXCL12 Production by Mature Dendritic Cells Inhibits the Propagation of X4-Tropic HIV-1 Isolates at the Dendritic Cell-T-Cell Infectious Synapse. <i>Journal of Virology</i> , 2010, 84, 4341-4351.	3.4	25
98	Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen. <i>Biochemical Pharmacology</i> , 2016, 107, 14-28.	4.4	25
99	Axonal Computations. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 413.	3.7	25
100	Expression of $\text{I}\kappa\text{B}\alpha$ in the nucleus of human peripheral blood T lymphocytes. <i>Oncogene</i> , 1999, 18, 1581-1588.	5.9	24
101	PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients. <i>Journal of Clinical Investigation</i> , 2020, 130, 2872-2887.	8.2	24
102	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. <i>PLoS ONE</i> , 2018, 13, e0193773.	2.5	24
103	Antagonistic modulation of human cytomegalovirus replication by transforming growth factor beta and basic fibroblastic growth factor. <i>Journal of General Virology</i> , 1993, 74, 269-274.	2.9	23
104	Ellagitannins from <i>Tuberaria lignosa</i> as entry inhibitors of HIV. <i>Phytomedicine</i> , 2010, 17, 69-74.	5.3	23
105	Hydroxytyrosol. <i>Aids</i> , 2016, 30, 2767-2776.	2.2	23
106	Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU. <i>Frontiers in Immunology</i> , 2021, 12, 742631.	4.8	23
107	Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription. <i>Biochemical Pharmacology</i> , 2015, 94, 241-256.	4.4	22
108	The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection. <i>PLoS Pathogens</i> , 2019, 15, e1007958.	4.7	22

#	ARTICLE	IF	CITATIONS
109	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. <i>Scientific Reports</i> , 2019, 9, 5606.	3.3	22
110	Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. <i>Antiviral Therapy</i> , 2004, 9, 545-54.	1.0	22
111	c/EBP1 ² Is a Major Regulatory Element Driving Transcriptional Activation of the CXCL12 Promoter. <i>Journal of Molecular Biology</i> , 2010, 396, 463-472.	4.2	21
112	Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: A potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells. <i>PLoS ONE</i> , 2017, 12, e0185677.	2.5	21
113	Guatemalan plants extracts as virucides against HIV-1 infection. <i>Phytomedicine</i> , 2008, 15, 520-524.	5.3	20
114	Molecular Phenotype of CXCL12β 3'UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression. <i>Current HIV Research</i> , 2009, 7, 384-389.	0.5	20
115	Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. <i>PLoS ONE</i> , 2017, 12, e0186602.	2.5	20
116	An in Vivo Functional Immune System Lacking Polyclonal T-Cell Surface Expression of the CD3/Ti(WT31) Complex. <i>Scandinavian Journal of Immunology</i> , 1987, 26, 699-707.	2.7	19
117	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. <i>BMC Medicine</i> , 2018, 16, 30.	5.5	19
118	A small-molecule inhibitor of HIV-1 Rev function detected by a diversity screen based on RRE-Rev interference. <i>Biochemical Pharmacology</i> , 2018, 156, 68-77.	4.4	19
119	Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. <i>PLoS Pathogens</i> , 2022, 18, e1010171.	4.7	18
120	Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. <i>Virus Genes</i> , 2007, 34, 111-116.	1.6	17
121	Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates. <i>Aids</i> , 2016, 30, 1015-1025.	2.2	17
122	Ethanol extract of <i>Artemisia campestris</i> subsp. <i>glutinosa</i> (Besser) Batt. inhibits HIV-1 replication in vitro through the activity of terpenes and flavonoids on viral entry and NF- κ B pathway. <i>Journal of Ethnopharmacology</i> , 2020, 263, 113163.	4.1	17
123	Natural Human Antibodies Retrieved by Phage Display Libraries from Healthy Donors: Polyreactivity and Recognition of Human Immunodeficiency Virus Type 1 gp120 Epitopes. <i>Scandinavian Journal of Immunology</i> , 1999, 50, 270-279.	2.7	16
124	Immune Activation Promotes Evolutionary Conservation of T-Cell Epitopes in HIV-1. <i>PLoS Biology</i> , 2013, 11, e1001523.	5.6	16
125	Electrical Synapses Enhance and Accelerate Interneuron Recruitment in Response to Coincident and Sequential Excitation. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 156.	3.7	15
126	Anti-HIV activity of some synthetic lignanoides and intermediates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 4483-4486.	2.2	14

#	ARTICLE	IF	CITATIONS
127	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. <i>Biochemical Pharmacology</i> , 2018, 156, 248-264.	4.4	14
128	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 667-671.	3.1	14
129	Dual role of host cell factors in HIV-1 replication: restriction and enhancement of the viral cycle. <i>AIDS Reviews</i> , 2010, 12, 103-12.	1.0	14
130	A novel factor distinct from E2F mediates C-MYC promoter activation through its E2F element during exit from quiescence. <i>Carcinogenesis</i> , 2009, 30, 440-448.	2.8	13
131	MAZ induces MYB expression during the exit from quiescence via the E2F site in the MYB promoter. <i>Nucleic Acids Research</i> , 2017, 45, 9960-9975.	14.5	13
132	Dasatinib protects humanized mice from acute HIV-1 infection. <i>Biochemical Pharmacology</i> , 2020, 174, 113625.	4.4	13
133	Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. <i>Journal of Clinical Medicine</i> , 2021, 10, 42.	2.4	13
134	Broadly Neutralizing Antibodies and their Significance for HIV-1 Vaccines. <i>Current HIV Research</i> , 2010, 8, 602-612.	0.5	12
135	Transcription elongation regulator 1 (TCERG1) regulates competent RNA polymerase II-mediated elongation of HIV-1 transcription and facilitates efficient viral replication. <i>Retrovirology</i> , 2013, 10, 124.	2.0	12
136	Determination of HIV tropism and its use in the clinical practice. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 1291-1302.	4.4	12
137	Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 547-559.	2.4	12
138	Natural killer cells act as an extrinsic barrier for <i>in vivo</i> reprogramming. <i>Development (Cambridge)</i> , 2022, 149, .	2.5	12
139	Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants. <i>Antiviral Research</i> , 2010, 88, 152-159.	4.1	11
140	Insight in miRNome of Long-Term Non-Progressors and Elite Controllers Exposes Potential RNAi Role in Restraining HIV-1 Infection. <i>Journal of Clinical Medicine</i> , 2020, 9, 2452.	2.4	11
141	CCR5 genotype and HIV-1 infection in perinatally-exposed infants. <i>Journal of Infection</i> , 1999, 38, 9-11.	3.3	10
142	A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1. <i>HIV Medicine</i> , 2008, 9, 160-171.	2.2	10
143	Generation and Characterization of a Defective HIV-1 Virus as an Immunogen for a Therapeutic Vaccine. <i>PLoS ONE</i> , 2012, 7, e48848.	2.5	10
144	Functional Consequences for Apoptosis by Transcription Elongation Regulator 1 (TCERG1)-Mediated Bcl-x and Fas/CD95 Alternative Splicing. <i>PLoS ONE</i> , 2015, 10, e0139812.	2.5	10

#	ARTICLE	IF	CITATIONS
145	Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients. PLoS ONE, 2019, 14, e0220459.	2.5	10
146	4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat. Biochemical Pharmacology, 2020, 177, 113937.	4.4	10
147	Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis. PLoS Pathogens, 2021, 17, e1009526.	4.7	10
148	Characterization of LEDGF/p75 Genetic Variants and Association with HIV-1 Disease Progression. PLoS ONE, 2012, 7, e50204.	2.5	10
149	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. Journal of Virology, 2022, 96, JVI0134321.	3.4	10
150	HIV-1 latency and eradication of long-term viral reservoirs. Discovery Medicine, 2010, 9, 185-91.	0.5	10
151	PKC ζ and HIV-1 Transcriptional Regulator Tat Co-exist at the LTR Promoter in CD4+ T Cells. Frontiers in Immunology, 2016, 7, 69.	4.8	9
152	Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Biochemical Pharmacology, 2020, 182, 114203.	4.4	9
153	Nucleic acid recognition and antiviral activity of 1,4-substituted terphenyl compounds mimicking all faces of the HIV-1 Rev protein positively-charged α -helix. Scientific Reports, 2020, 10, 7190.	3.3	9
154	Use of RT-Defective HIV Virions: New Tool to Evaluate Specific Response in Chronic Asymptomatic HIV-Infected Individuals. PLoS ONE, 2013, 8, e58927.	2.5	9
155	Hot Immunological Topics in HIV Infection. Journal of AIDS & Clinical Research, 2011, 02, .	0.5	9
156	In vitro selective elimination of HIV-infected cells from peripheral blood in AIDS patients by the immunotoxin DAB389CD4. Aids, 1998, 12, 859-863.	2.2	8
157	Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1365-1382.	3.3	8
158	Impact of Transcriptome and Gut Microbiome on the Response of HIV-1 Infected Individuals to a Dendritic Cell-Based HIV Therapeutic Vaccine. Vaccines, 2021, 9, 694.	4.4	8
159	Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. Biochemical Pharmacology, 2021, 192, 114666.	4.4	8
160	INDOMETHACIN IN THE RELIEF OF AIDS SYMPTOMS. Lancet, The, 1986, 328, 570.	18.7	7
161	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology, 2012, 9, 68.	2.0	7
162	Neoflavonoids as Inhibitors of HIV-1 Replication by Targeting the Tat and NF- κ B Pathways. Molecules, 2017, 22, 321.	3.8	7

#	ARTICLE	IF	CITATIONS
163	An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies. PLoS ONE, 2016, 11, e0166902.	2.5	7
164	Reverse transcriptase-like activity in <i>Trypanosoma cruzi</i> . Acta Tropica, 1997, 63, 117-126.	2.0	6
165	Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins. Journal of Virological Methods, 2016, 236, 184-195.	2.1	6
166	5-Hydroxytyrosol inhibits HIV-1 replication in primary cells of the lower and upper female reproductive tract. Antiviral Research, 2017, 142, 16-20.	4.1	6
167	Different Expression of Interferon-Stimulated Genes in Response to HIV-1 Infection in Dendritic Cells Based on Their Maturation State. Journal of Virology, 2017, 91, .	3.4	6
168	Promiscuous, Multi-Target Lupane-Type Triterpenoids Inhibits Wild Type and Drug Resistant HIV-1 Replication Through the Interference With Several Targets. Frontiers in Pharmacology, 2018, 9, 358.	3.5	6
169	In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. Journal of Medical Virology, 2009, 81, 211-216.	5.0	5
170	Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV. Current HIV/AIDS Reports, 2019, 16, 414-422.	3.1	5
171	Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19. Journal of Clinical Medicine, 2022, 11, 2803.	2.4	5
172	Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study. EClinicalMedicine, 2022, 51, 101542.	7.1	5
173	Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients. Pharmacogenomics, 2014, 15, 569-572.	1.3	4
174	Potential role of tyrosine kinase inhibitors during primary HIV-1 infection. Expert Review of Anti-Infective Therapy, 2017, 15, 421-423.	4.4	4
175	Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFN- γ Mediation. Journal of Clinical Medicine, 2020, 9, 959.	2.4	4
176	Withanolide-Type Steroids from <i>Physalis nicandroides</i> Inhibit HIV Transcription. Journal of Natural Products, 2021, 84, 2717-2726.	3.0	4
177	Elevated $\hat{\pm}$ -Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control. Frontiers in Immunology, 2022, 13, 822272.	4.8	4
178	The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans. IScience, 2022, , 104409.	4.1	4
179	Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors. Journal of Medical Virology, 2004, 73, 502-507.	5.0	3
180	Situaci3n de la investigaci3n sobre el VIH en Espa3a. Enfermedades Infecciosas Y Microbiolog3a Cl3nica, 2018, 36, 26-30.	0.5	3

#	ARTICLE	IF	CITATIONS
181	Association of a single nucleotide polymorphism in the ubxn6 gene with long-term non-progression phenotype in HIV-positive individuals. <i>Clinical Microbiology and Infection</i> , 2020, 26, 107-114.	6.0	3
182	Association of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individuals. <i>Vaccines</i> , 2021, 9, 799.	4.4	3
183	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. <i>EClinicalMedicine</i> , 2022, 50, 101529.	7.1	3
184	CD11b-bearing mononuclear leucocytes and IgA levels in the staging of human immunodeficiency virus infection. <i>Experientia</i> , 1992, 48, 402-404.	1.2	2
185	Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients. <i>Virology</i> , 2017, 500, 247-258.	2.4	2
186	Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc. <i>Journal of Virology</i> , 2018, 92, .	3.4	2
187	Evolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllers. <i>Frontiers in Immunology</i> , 2021, 12, 730691.	4.8	2
188	Avances en la inmunopatología de la infección por el VIH. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2004, 22, 486-496.	0.5	2
189	Extensive GJD2 Expression in the Song Motor Pathway Reveals the Extent of Electrical Synapses in the Songbird Brain. <i>Biology</i> , 2021, 10, 1099.	2.8	2
190	Where does free infective HIV-1 rebound come from?. <i>Aids</i> , 2001, 15, 657.	2.2	2
191	Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. <i>Blood</i> , 2019, 134, 191-191.	1.4	2
192	Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection. <i>Journal of Clinical Medicine</i> , 2022, 11, 2137.	2.4	2
193	P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group. <i>Retrovirology</i> , 2009, 6, .	2.0	1
194	Molecular mechanisms involved in HIV latency and implications for HIV treatment and eradication. <i>Retrovirology</i> , 2010, 7, .	2.0	1
195	Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMD2) Contributes to Resistance to HIV-1 Infection. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	3.7	1
196	Anti-HIV Activity of Some Synthetic Lignanoides and Intermediates.. <i>ChemInform</i> , 2004, 35, no.	0.0	0
197	Situación actual en el desarrollo de una vacuna preventiva frente al VIH. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2005, 23, 5-14.	0.5	0
198	Modifications in host cell structure and functions mediated by Tat intracellular expression are greatly dependent on the second exon. <i>Retrovirology</i> , 2009, 6, .	2.0	0

#	ARTICLE	IF	CITATIONS
199	Allosteric regulation by non peptidic, low molecular weight compounds of CCR5 coupling to g-proteins and interaction with Gp120 - consequences on inhibition of R5 HIV-1 infection. <i>Retrovirology</i> , 2010, 7, .	2.0	0
200	Innenr¼cktitelbild: Structure-Based Design of an RNA-Bindingp-Terphenylene Scaffold that Inhibits HIV-1 Rev Protein Function (<i>Angew. Chem.</i> 50/2013). <i>Angewandte Chemie</i> , 2013, 125, 13719-13719.	2.0	0
201	Antiviral Activity of 5-Hydroxytyrosol, a Microbicidal Candidate against HIV-1 Transmission. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A240-A240.	1.1	0
202	Candidate Microbicide 5-hydroxytyrosol (5-HT) Inhibits Productive R5 HIV-1 Infection of Human Cervical Tissue Explants (CTE). <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A264-A264.	1.1	0
203	Combinations of Entry and Reverse Transcriptase Inhibitors as Candidate Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A213-A213.	1.1	0
204	Mucosal Tissue Explants as Surrogates for <i>In Vivo</i> Efficacy of Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A60-A60.	1.1	0
205	Preclinical Evaluation of Multi-targeting Antiretroviral Drug Based-combinations as Candidate Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A262-A262.	1.1	0
206	Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum. <i>Journal of Virus Eradication</i> , 2017, 3, 236-241.	0.5	0
207	Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum. <i>Journal of Virus Eradication</i> , 2017, 3, 236-241.	0.5	0
208	Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients. <i>Frontiers in Virology</i> , 2022, 2, .	1.4	0
209	Omic Technologies in HIV: Searching Transcriptional Signatures Involved in Long-Term Non-Progressor and HIV Controller Phenotypes. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0